Chemotherapy plus immunotherapy for recurrent small-cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two drugs—a type of chemotherapy called paclitaxel (in a special micelle formulation, like a tiny carrier) plus an immunotherapy called ivonescimab—for people whose small-cell lung cancer has returned after standard treatment. The goal is to see if this combo can help shrink tumors and slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have small-cell lung cancer that has come back after you received at least one standard treatment, which included a platinum chemotherapy (like carboplatin) and an immunotherapy (like a PD-1/PD-L1 blocker).
- You must have at least one tumor that can be measured on a scan.
- You should be able to take care of yourself (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- Your heart, liver, kidneys, and blood cell counts must be within safe ranges, and you must not have certain heart or bleeding conditions.
- You must not have had a taxane chemotherapy (like paclitaxel) or a blood-vessel-targeting drug (like bevacizumab) before, and you must not have untreated or symptomatic brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving standard chemotherapy and radiation together with two types of immunotherapy (which helps your immune system fight cancer) for limited-stage small cell lung cancer. The goal is to see if adding these immune treatments improves outcomes compared to standard care.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
This trial tests a combination of two medicines — a chemotherapy called irinotecan liposome and an immunotherapy called ivonescimab — for people whose small cell lung cancer has returned or progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
Hear when a new SCLC, Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.